abilify- aripiprazole tablet abilify- aripiprazole solution abilify- aripiprazole tablet, orally disintegrating abilify- arip
otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea
sodium chloride 0.18% & glucose 4.3% i.v.infusion b.p 2003
otsuka egypt - injection
ns injection
claris otsuka private limited village - vasna chacharwadi tal. sanand - sodium chloride bp - injection - 0.9 % w/v - intravenous solutions: solutions for parenteral
otsuka glucose injection 10% (20ml) (大塚糖液10%(20ml))
otsuka pharmaceutical factory, inc. - purified glucose - injection
compound sodium lactate intravenous infusion bp
luen wah medical company (singapore) private limited - calcium chloride; lactic acid; potassium chloride; sodium chloride; sodium hydroxide - injection - 0.027 g/100 ml - calcium chloride 0.027 g/100 ml; lactic acid 0.24 ml/100 ml; potassium chloride 0.04 g/100 ml; sodium chloride 0.6 g/100 ml; sodium hydroxide 0.115 g/100 ml
celemin 10 plus 10% w/ v 10% w/v intravenous injection
otsuka (phils.) pharmaceutical, inc.; distributor: zyre pharmaceutical corp. - amino acids , electrolytes - 10% w/v intravenous injection - 10% w/ v
busulfex busulfan 60mg/10ml injection vial
otsuka australia pharmaceutical pty ltd - busulfan, quantity: 60 mg - injection - excipient ingredients: dimethylacetamide; macrogol 400 - busulfex is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.
magnesium sulfate 10% injection u.s.p 27
otsuka egypt - injection - 10 %
super amp solution 10
otsuka pharmaceutical india private limited, india - sterilised water for injection - solution - 10
busulfex® injection 60 mgvial
steward cross pte ltd - busulfan - injection, solution, concentrate - 60 mg/vial - busulfan 60 mg/vial